Urgent.News

What's breaking now, across thousands of outlets.

AI

Isomorphic Labs and MSD team up on AI-led cancer drug discovery

The partnership will see both organisations collaborate on oncology drug therapies designed to target small molecules. Read more: Isomorphic Labs and MSD team up on AI-led cancer drug discovery

Isomorphic Labs and MSD team up on AI-led cancer drug discovery

Alphabet’s Isomorphic Labs and pharmaceutical giant MSD are joining forces to discover new cancer drugs aimed at a key target. The collaboration will merge Isomorphic Labs’ cutting-edge AI technology with MSD’s extensive data resources. Isomorphic Labs will employ in silico prediction, a computational approach used in drug discovery, to design potential new therapeutic small molecules.

MSD will contribute its data sets, expertise in pre-clinical and clinical development, and support in bringing any resulting medicines to market. The partnership agreement outlines that Isomorphic Labs will receive an initial payment from MSD, along with additional payments contingent on the achievement of specific research, development, regulatory, and commercial milestones.

Isomorphic Labs recently raised $5 billion in Series C funding, with participation from various investors including Greenoaks, Sequoia Capital, and Alphabet. The collaboration aims to harness the power of AI and machine learning to accelerate the discovery of new cancer drugs, addressing a significant unmet need for patients.

Written by urgent.news from Silicon Republic's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at siliconrepublic.com →

More in AI

More from Friday 20 November →